We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

January 24, 2019

The New Framework for Digital Health Decision Making in the NHS

Hanna Phelan
&

What is NICE and what are their DH Guidelines?  

What does a ‘good’ digital health solution look like? Is ‘good’ even enough when it comes to putting a digital solution in a patient’s hands? In the flurry of the end of 2018, some of you may have missed a notable milestone in the evolution of digital health in the UK, the release of the Evidence standards framework for digital health technologies . In December, The National Institute for Health and Care Excellence (NICE), an executive non-departmental public body of the Department of Health in the United Kingdom that publishes quality standards and guidelines on all aspects on healthcare in the country, released these guidelines for digital health solutions signalling both the increasing maturity of these solutions and the surmounting confusion of how to actually implement them in a functioning health system.


The aim of the standards is three fold:




The NICE framework focuses on the above areas within the frame of evidence for economic impact standards and clinical evidence based on the intended use of ranging from Digital Health Technologies (DHTs) with potential system benefits but no direct user benefits, to those used for direct treatment and diagnosis, as well as those influencing clinical management. In the following we’ll take a further look at what value these guidelines offer, their limitations, and what this may mean for the space going forward.



Why does the NHS need this?

Some innovators in digital health seem to have a ‘move fast and break things’ approach. How do we balance this with an evidence hungry clinical environment? Like many things, it comes down to communicating in a shared vocabulary. The NICE guidelines are a welcome shared currency, facilitating interactions between previously disparate stakeholders.


“We have seen a number of DHT solutions come on the market in recent years. Some have been good and some not so good, but what we have really struggled with is defining a shared standard of what good looks like.”
Dr Indra Joshi,  Digital Programme Clinical Lead at NHS England


According to the HealthXL data platform, between 2000-2018 there have been approximately 2174 healthcare investments in the UK spanning more than $16M. In accordance with mortality and morbidity trends, and growing confidence and capacity of new technologies and methodologies there appears to have been a significant investment focus on cancer interventions, genetic and genomic efforts paving the way for more personalised care, in addition to investment in chronic conditions such as cardiac health and respiratory conditions.


What is apparent from this investment insight and the demographic data of the NHS is that digital is being very seriously considered and engaged with in terms of preventative, primary, secondary and tertiary care.  Within each of these therapeutic areas or use cases there will be a plethora of different DHTs on offer making these guidelines and future iterations absolutely necessary in order to tame the beast.


Source: HealthXL Data Platform



What Value do the NICE Guidelines Add?

So, what do these standards actually say and what value do they add? Essentially the framework positively contributes the following:


  1. Provides digital health startups and innovators a clear guideline as to what they are being measured against


  1. Validates digital health solutions by holding them to the same standard of investigation as traditional pharmaceutical drugs


  1. Encourages the adoption of digital solutions from within healthcare facilities - providing a clear path to adoption and consistency in evaluation - NHS commissioners know what to look for and companies know what to expect from these requirements


  1. Accepts realistic expectations the evidence level required for each tier is proportionate to the potential risk to users presented by the DHTs in that tier. This is a similar approach to how FDA classify and evaluate companies and signals towards increased international alignment of standards which may facilitate accelerated DH scale


The clinical grades attributed by the NICE guidelines ranges between a scale of 1 to 3b, the latter being the highest category of risk and therefore pinned to the expectation of the highest standard of clinical evidence, an RCT, in addition to meeting preceding expectation of clinical validation expected of the lower risk solutions. Lower categories focus on apps that provide information and advice on healthy lifestyles or collect information for personal health diaries. Higher categories can include technologies that perform clinical calculations or use data to diagnose a condition to inform decisions made by healthcare professionals. This provides a benchmark for what is the minimally viable point that a DHT could even be considered for NHS support.


In terms of economic impact standards, the NICE framework is slightly less elaborated upon in comparison to the attention attributed to clinical evidence. Having said this, there is value to be found in linking the clinical efficacy and economic impact side-by-side as a strong reminder of the need to start with a real measurable problem and to bare in mind that any solution used by an NHS population will have to somehow be paid for.


Similar to the risk stratification model used for the clinical evidence requirements, the NICE framework maps out a template for evaluating evidence of economic impact from a payer perspective. This, in addition to some of the other economic elements, gives new and pre-existing NHS DHT companies the chance to see the key elements of their grading scheme when it comes to likelihood of being reimbursed or supported by NHS bodies.


One key contribution for startups here is the detailed guidance Budget Impact Template provided by the collaborative in order to help innovators using the economic impact standards. This carries innovators through a relatively rigorous pathway, evaluating everything from unit costs to sensitivity analysis.


Limitations and Potential Future Iterations




Tier 3a allows for control group to have no intervention, requiring ‘A high quality quasi-experimental or experimental study would compare the effect of the DHT on a group of users with 1 or more groups having a different (or no) treatment.’ . In terms of Tier 3b there is a comparative requirement for a control group, however this is far from a clear-cut avenue as the global digital health community realizes the difficulty in determining what actually constitutes an appropriate DHT control intervention. Here there is a potential need for future iterations of the guidelines to more rigorously provide guidance on how to determine an appropriate control for different types of solutions. This gives way to a much bigger question - is our ‘gold standard’ RCT in its current form a fit for evaluating DHTs?



“It is a significant step forward for the NHS market to now have the first Evidence standards framework for digital health solutions. Digital health has seen rapid growth over the past five years and inevitably there is a significant degree of variation both in terms of applications (wellness to clinical) as well as quality (few digital solutions have robust evaluations). Creating clear standards is therefore important both for entrepreneurs to create a level playing field but also for patients and healthcare professionals to separate the wheat from chaff.
The standards are a first attempt and will inevitably continue to develop over time. Alongside the FDA framework, they may also shape global standards.
The biggest challenge going forward will be to more comprehensively cover dynamic solutions such as ML and AI algorithms. These applications have the added challenge that their efficacy keeps evolving over time which requires new methodology to assess their impact. This could take the form of digi-covigilance similar to pharmacovigilance requiring longitudinal and quality data sets. It also overlaps with ethical considerations about the transparency of ML and AI.”
Dr Axel Heitmueller, Managing Director @ Imperial College Health Partners


And Finally...


What We Know:


What Next:


The collaborative group, highlighted below, leading the change for the NICE guidelines are cognisant of this ever shifting environment and have already shared that a second iteration of the guidelines will be released in February 2019 following the initial feedback from various stakeholders in the NHS system and innovator community. While there are many unknowns in global development and implementation of digital health solutions, the NICE guidelines champion the core elements that must remain a constant benchmark for success - the need for validation of clinical efficacy and cost effectiveness.


Collaborative Authors of the Framework





We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: How to Navigate the NHS Digital Technology Assessment Criteria and NICE evidence guidelines

1st February @ 10AM GMT / 6PM AWST

Are you trying to increase adoption and use of your Digital Health solution across the UK's National Health Service? Join your peers in this meeting as they deep dive into this topic. Apply now to secure your place as seats are limited.

Featuring
Richard Bunney
Richard Bunney
Director, Cuniculo Ltd
Featuring
Richard Bunney
Richard Bunney
Director, Cuniculo Ltd
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Endpoints and Control Arms in Trials for DTx

15th February @ 10:45AM EDT

Proving clinical efficacy is one of the biggest challenges for DTx companies. Apply now to join HealthXL in this session to dive deeper into this topic with leaders in this field.

Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Featuring
Acacia Parks
Acacia Parks
Chief Science Officer, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

The Role of the Consumer Experience in DTx

15th February @ 10:45AM EDT

As technology advances in all sectors (e.g. fintech, entertainment, etc), consumer behaviour changes and the expectations on user experience are higher than before. Apply now to secure your place in this meeting where you will dive deeper into this topic with your peers.

Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Featuring
Lee Shapiro
Lee Shapiro
Managing Partner, 7wireVentures
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Incorporating Extended Reality (XR) in Physician's’ Daily Work

28th February @ 10:45AM EDT

The healthcare industry is undergoing a digital transformation and extended reality (XR) technologies such as virtual reality (VR) and augmented reality (AR) are expected to play a significant role in this change in the next few years. Apply now to join this Masterclass led by Nemanja Kovačev, MedTech Expert at HTEC Group.

Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group
Featuring
Nemanja Kovačev
Nemanja Kovačev
MedTech Expert, HTEC Group

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Health in Oncology
31st January @ 10:45AM EDT

Are Hospitals the Right Partner for Digital Health Companies in Oncology?

Digital health in oncology is still a very raw and undefined practice with companies still searching for a best approach to put these solutions into the patients' hands. Join this peer-to-peer conversation to deep dive into this discussion.

Eoin Tabb
Featuring
Eoin Tabb
A/ Chief II Pharmacist, Cancer Services, HSE
Clinical Trials Innovation
1st February @ 11AM EDT

HealthXL Webinar: The Potential of AI in Drug Discovery

The drug discovery process has traditionally been costly and very time-consuming. Join this Webinar to deep dive into this topic with senior leaders in this area.

Armen Vidian
Featuring
Armen Vidian
Digital Health Venture Capitalist
Digital Therapeutics (DTx)
1st February @ 10AM GMT / 6PM AWST

Masterclass: How to Navigate the NHS Digital Technology Assessment Criteria and NICE evidence guidelines

Are you trying to increase adoption and use of your Digital Health solution across the UK's National Health Service? Join your peers in this meeting as they deep dive into this topic. Apply now to secure your place as seats are limited.

Richard Bunney
Featuring
Richard Bunney
Director, Cuniculo Ltd
Telemedicine & Virtual Care Delivery
2nd February @ 10:45AM EDT

Masterclass: How to Make Value-Based Health Care (VBHC) work with Digital Health?

Would you like to learn more about value-based health care models (VBHC) and the interplay between these systems and digital health solutions? Join HealthXL in this Masterclass led by Matt Hickey to deep dive into this topic. Seats are limited so apply now to secure your place.

Matt Hickey
Featuring
Matt Hickey
CEO, The Health Value Alliance

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.